Related Experiment Videos
Hemobiology, vascular disease, and diabetes with special reference to impaired fibrinolysis
P Vague1, D Raccah, I Juhan-Vague
1Department of Diabetes, University Hospital Timone, Marseille, France.
Insights
Diabetes significantly increases the risk of ischemic cardiovascular events by impairing fibrinolysis, the body's clot-dissolving process. This review highlights the critical link between diabetes and reduced fibrinolytic activity, contributing to cardiovascular disease.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Thrombosis Research
Background:
- Diabetes mellitus is a major risk factor for cardiovascular disease.
- Atherothrombosis, the underlying pathology of ischemic events, is closely linked to diabetes.
- Impaired fibrinolysis is increasingly recognized as a significant contributor to cardiovascular pathology.
Purpose of the Study:
- To review the intricate relationship between diabetes and the development of ischemic cardiovascular events.
- To specifically focus on the role of impaired fibrinolysis in diabetic patients.
- To emphasize the importance of fibrinolysis in the context of diabetes-related cardiovascular complications.
Main Methods:
- Literature review focusing on pathogenetic pathways of atherothrombosis in diabetes.
- Analysis of studies investigating fibrinolysis in diabetic individuals.
- Synthesis of current understanding on the interaction between diabetes and fibrinolytic function.
Main Results:
- Diabetes is associated with multiple pathophysiological interactions leading to ischemic cardiovascular events.
- The main pathogenetic pathways of atherothrombosis are frequently analyzed in relation to diabetes.
- Fibrinolysis is consistently found to be impaired in diabetic patients, a critical factor in cardiovascular disease.
Conclusions:
- Impaired fibrinolysis is a key, recently recognized factor in cardiovascular disease among diabetic patients.
- Understanding the link between diabetes and impaired fibrinolysis is crucial for managing cardiovascular risk.
- Further research into enhancing fibrinolytic function in diabetes may offer new therapeutic strategies.
Abstract:
This brief review is intended to emphasize the multiple interactions between diabetes and the pathophysiological processes that lead to ischemic cardiovascular events. The main pathogenetic pathways of atherothrombosis and their relationship with diabetes are largely and frequently analyzed. In this review, we will focus on a particular aspect of this pathological process, namely, the impairment in fibrinolysis, the importance of which has been recently recognized in cardiovascular disease. Fibrinolysis is frequently impaired in diabetic patients.